A primer to gene therapy: Progress, prospects, and problems
Open Access
- 8 June 2020
- journal article
- review article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 44 (1), 54-71
- https://doi.org/10.1002/jimd.12270
Abstract
Genetic therapies based on gene addition have witnessed a variety of clinical successes and the first therapeutic products have been approved for clinical use. Moreover, innovative gene editing techniques are starting to offer new opportunities in which the mutations that underlie genetic diseases can be directly corrected in afflicted somatic cells. The toolboxes underpinning these DNA modifying technologies are expanding with great pace. Concerning the ongoing efforts for their implementation, viral vector‐based gene delivery systems have acquired center‐stage, providing new hopes for patients with inherited and acquired disorders. Specifically, the application of genetic therapies using viral vectors for the treatment of inborn metabolic disorders is growing and clinical applications are starting to appear. While the field has matured from the technology perspective and has yielded efficacious products, it is the perception of many stakeholders that from the regulatory side further developments are urgently needed. In this review, we summarize the features of state‐of‐the‐art viral vector systems and the corresponding gene‐centered therapies they seek to deliver. Moreover, a brief summary is also given on emerging gene editing approaches built on CRISPR‐Cas9 nucleases and, more recently, nickases, including base editors and prime editors. Finally, we will point at some regulatory aspects that may deserve further attention for translating these technological developments into actual advanced therapy medicinal products (ATMPs).Funding Information
- Duchenne Parent Project (17.012)
- H2020 Marie Skłodowska-Curie Actions (765269)
- Prinses Beatrix Spierfonds (W.OR16‐13)
This publication has 171 references indexed in Scilit:
- CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activityNucleic Acids Research, 2013
- Multiplex Genome Engineering Using CRISPR/Cas SystemsScience, 2013
- Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteriaProceedings of the National Academy of Sciences of the United States of America, 2012
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- Zinc-Finger Nucleases for Somatic Gene Therapy: The Next FrontierHuman Gene Therapy, 2011
- In vivo genome editing restores haemostasis in a mouse model of haemophiliaNature, 2011
- CRISPR RNA maturation by trans-encoded small RNA and host factor RNase IIINature, 2011
- Efficacy of Gene Therapy for X-Linked Severe Combined ImmunodeficiencyThe New England Journal of Medicine, 2010
- Insertional Transformation of Hematopoietic Cells by Self-inactivating Lentiviral and Gammaretroviral VectorsMolecular Therapy, 2009
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008